SILVIA
ORTEGA GUTIÉRREZ
Catedrática de universidad
JOSÉ JAVIER
FERNÁNDEZ RUIZ
Catedrático de universidad
Publicacións nas que colabora con JOSÉ JAVIER FERNÁNDEZ RUIZ (10)
2016
-
A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease
Journal of Neurology, Vol. 263, Núm. 7, pp. 1390-1400
2007
-
Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions
Life Sciences, Vol. 80, Núm. 10, pp. 979-988
2006
-
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders
European Neuropsychopharmacology, Vol. 16, Núm. 1, pp. 7-18
2005
-
Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels
Biochemical Pharmacology, Vol. 70, Núm. 3, pp. 446-452
2003
-
Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors
European Journal of Medicinal Chemistry
-
Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: Comparison with effects on fatty acid amidohydrolase
Journal of Medicinal Chemistry, Vol. 46, Núm. 8, pp. 1512-1522
2002
-
Endocannabinoid transporter inhibitors
Current Medicinal Chemistry - Central Nervous System Agents, Vol. 2, Núm. 2, pp. 129-141
-
UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide
European Journal of Pharmacology, Vol. 449, Núm. 1-2, pp. 99-103
2001
-
Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors
Journal of Medicinal Chemistry, Vol. 44, Núm. 26, pp. 4505-4508
-
Nuevas tendencias en la utilidad terapeútica de los cannabinoides
Anales de Química de la RSEQ, Núm. 2, pp. 14-21